The main contribution of the present study is to highlight that, in addition to reduced OCT1 expression (mRNA/protein) levels in the tumor, the reduction in functional OCT1 at the plasma membrane of tumor cells plays a key role among the multifactorial mechanisms of chemoresistance (MOC) determining the response of HCC to sorafenib. Here, SLC22A1 is linked to hepatocellular carcinoma.